CHESTY COUGH Criteria for INCLUSION Symptomatic relief of productive cough. Criteria for EXCLUSION Patients under two years. Cough productive of green/yellow/blood stained sputum. Chronic bronchitis. Asthmatics presenting with wheeze. Pregnant or breast-feeding patients. Patients identified as requiring conditional or rapid referral. Rapid referral Constant chest pain or chest pain on normal inspiration. Shortness of breath/difficulty breathing. Rusty or foul smelling sputum. Pain related to exertion. Fever and sweating Pain or swelling in the calf Patients experiencing recent sudden weight loss. Conditional referral If cough persists beyond two weeks the patient should consult the GP. Children under 12 years of age if appropriate. Patients with hepatic or renal impairment, cardiovascular disorders and patients at risk of seizures if appropriate. Action for excluded patients Referral to General Practitioner. Recommended treatments, frequency of administration and maximum dose Pseudoephedrine Linctus 30mg/5ml (100ml) Adults, elderly and children over 12 years: 10ml three times a day. Children aged 6 to 12 years: 2.5ml to 5ml three times a day. Child 2 to 6 years 2.5ml three times a day. Simple Linctus Paediatric (200ml) Children up to 12 years: 5ml to 10ml three to four times a day Ammonia and Ipecacuanha Mixture (200ml) Adults, elderly and children over 12 years: 10ml to 20ml up to a maximum of four times a day. Contra-indicated in children under 12 years (see note below) Children under 12 years may be offered advice only or referred to GP as appropriate.
Knowsley PCT Care at the Chemist Treatment Protocols February 2009
Product Reminder Systemic Decongestants:- Do not use for patients with diabetes, hyperthyroidism, hypertension, IHD, patients with raised intraocular pressure, prostatic hypertrophy, hepatic or renal impairment. Do not use in patients taking or have taken MAOIs in the preceeding 2 weeks. Do not supply during pregnancy or breast-feeding under the CATC scheme. Ammonia and Ipecacuanha mixture should not be used in patients under 12 years or in patients with hepatic or renal impairment, cardiovascular disorders or patients at risk from seizures. MHRA advice issued March 2008 National advice on treatment of coughs and colds in children under two was issued in March 2008. In summary, this advice is: • Children suffering from a cough or cold should be treated with paracetamol or ibuprofen to lower the child’s temperature, and if they have a cough to use a simple cough syrup (such as glycerol, honey or lemon); • Non-prescription cough and cold preparations containing any of these active substances should not be used in children under 2 years: Brompheniramine, Chlorphenamine, Dextrometorphan, Diphenhydramine, Ephedrine, Guaifenesin, Ipecacuanha, Oxymetazoline, Phenylephrine, Pholcodine, Pseudoephedrine & Xylometazoline • For children aged 2-6 years, care should be taken to adhere to the maximum daily dose; not to take with other cough and cold medicines; and the advice of a pharmacist or other healthcare professional should be sought if there are any concerns. Follow-up and advice Hydration of the airways by maintaining fluid intake and by humidifying inspired air by using steam inhalations – exercise caution with steam if children are present. Possible side effects Large doses of Ipecacuanha or ammonium salts may cause nausea and vomiting, however these effects would not be expected to occur when this preparation is taken at the recommended dose.
Knowsley PCT Care at the Chemist Treatment Protocols February 2009
U025-015-Sep2012-R Published on 10 September 2012 UNIFIED CARRIER LICENCE TELECOMMUNICATIONS ORDINANCE (CHAPTER 106) PCCW-HKT Telephone Limited (“PCCW-HKTC”) and Hong Kong Telecommunications (HKT) Limited (“HKT”) Name of Tariff: eye2 Communication Package Description of Tariff: See Annex A Effective date of tariff: 10 September 2012 Revision history: R
Prescription Drug Pricing in the United States: Drug Companies Profit at the Expense of Older Americans ______________________________________________________________________________ Minority Staff Special Investigations Division Committee on Government Reform U.S. House of Representatives November 9, 1999 Table of Contents Executive Summary . . . . . . . . . . . . .